{
    "clinical_study": {
        "@rank": "94119", 
        "arm_group": [
            {
                "arm_group_label": "Empagliflozin low dose", 
                "arm_group_type": "Experimental", 
                "description": "Empagliflozin low dose tablet once daily"
            }, 
            {
                "arm_group_label": "Empagliflozin high dose", 
                "arm_group_type": "Experimental", 
                "description": "Empagliflozin high dose tablet once daily"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo tablet once daily"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the efficacy of empagliflozin administered orally once daily in postprandial\n      glucose and 24-hour glycaemic variability compared to placebo given for 4 weeks as\n      mono-therapy in Japanese patients with type 2 diabetes mellitus with insufficient glycaemic\n      control on no antidiabetic treatment."
        }, 
        "brief_title": "Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Diabetes Mellitus, Type 2", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Diagnosis of type 2 diabetes mellitus prior to informed consent\n\n          -  Male and female patients on diet and exercise regimen for 12 weeks prior to informed\n             consent who are:\n\n               -  drug-na\u00efve, defined as no antidiabetic drugs for at least 12 weeks prior to\n                  informed consent or,\n\n               -  pre-treated with one oral antidiabetic drug (except sulfonylurea and\n                  thiazolidinedione); the present antidiabetic therapy has to be unchanged for at\n                  least 12 weeks prior to the informed consent. (Sulfonylurea is permitted as\n                  pre-treatment drug only if the dose is equal or less than a half of daily\n                  maximum approval dose.)\n\n          -  Glycosylated haemoglobin (HbA1c) at Visit 1 (screening)\n\n               -  for patients without antidiabetic therapy : HbA1c >=7.0 to =<10.0%\n\n               -  for patients with one oral antidiabetic drug : HbA1c >=7.0 to =<9.5%\n\n        Exclusion criteria:\n\n          -  Uncontrolled hyperglycaemia with a glucose level >240 mg/dL (>13.3 mmol/L)\n\n          -  Impaired renal function, defined as estimated glomerular filtration rate (eGFR) <60\n             mL/min/1.73m2 (moderate and severe renal impairment, modification of diet in renal\n             disease (MDRD) formula)\n\n          -  Acute coronary syndrome, stroke or transient ischemic attack (TIA) within 12 weeks\n             prior to informed consent\n\n          -  Indication of liver disease, defined by serum levels of either alanine transaminase\n             (ALT), aspartate transaminase (AST), or alkaline phosphatase (ALP) above 3 x upper\n             limit of normal (ULN)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01947855", 
            "org_study_id": "1245.35"
        }, 
        "intervention": [
            {
                "arm_group_label": "Empagliflozin high dose", 
                "description": "Placebo tablet matching Empagliflozin low dose", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Empagliflozin low dose", 
                "description": "Empagliflozin low dose", 
                "intervention_name": "Empagliflozin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo tablet matching Empagliflozin high dose", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo tablet matching Empagliflozin low dose", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Empagliflozin high dose", 
                "description": "Empagliflozin high dose tablet once daily", 
                "intervention_name": "Empagliflozin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Empagliflozin low dose", 
                "description": "Placebo tablet matching Empagliflozin high dose", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "January 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Shinjyuku-ku, Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "1245.35.002 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suita-shi, Osaka", 
                        "country": "Japan"
                    }, 
                    "name": "1245.35.001 Boehringer Ingelheim Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomised, Double-blind, Placebo-controlled, Parallel Group, 4-week Study to Evaluate the Efficacy of Empagliflozin (10 mg and 25 mg Administered Orally Once Daily) in Postprandial Glucose and 24-hour Glucose Variability in Japanese Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "change in area under the concentration-time curve (AUC1-4h) for postprandial plasma glucose from baseline after 28 days of treatment", 
            "safety_issue": "No", 
            "time_frame": "day 28"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01947855"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "collaborator": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}